États-Unis · Places boursières & cours · Nasdaq

BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate

Publié par Nasdaq · États-Unis il y a 1 h

(RTTNews) - On Monday, BioNTech (BNTX) and DualityBiologics, subsidiary of Duality Biotherapeutics (9606.HK) said trastuzumab pamirtecan met the primary endpoint in the Phase 3…

Lire l'article complet sur Nasdaq Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.nasdaq.com)

BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate

À lire aussi

U.S. Army Says It Has Helped 1.5 Billion Barrels of Oil Out of Hormuz

Latest Monero (XMR) Price Analysis

Warren Buffett’s Value Investing Strategy for Wealth: Patience and Quality

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog

BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate

Partager

À lire aussi

U.S. Army Says It Has Helped 1.5 Billion Barrels of Oil Out of Hormuz

Latest Monero (XMR) Price Analysis

Warren Buffett’s Value Investing Strategy for Wealth: Patience and Quality

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog